Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | RHOC | P08134 | 2/20 | 0.49 |
| ▸ | RHOA | P61586 | 2/20 | 0.49 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 2/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.43 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.43 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.43 |
| ▸ | ITGA8 | P53708 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615919 | 0.90 | TACR1 (0.59) | TACR1RHOCRHOAEGLN1MLYCD | |
| SCHEMBL14528862 | 0.86 | RHOC (0.48) | TACR1RHOCRHOADDR1VNN1 | |
| SCHEMBL3898783 | 0.83 | KDM4E (0.53) | TACR1RHOCRHOAEGLN1HTT | |
| SCHEMBL13753001 | 0.83 | DDR1 (0.55) | TACR1RHOCRHOADDR1VNN1 | |
| Hydrochloric Acid SCHEMBL6776606 | 0.82 | KDM4E (0.51) | TACR1RHOCRHOAEGLN1HTT | |
| SCHEMBL28429392 | 0.81 | TACR1 (0.47) | TACR1RHOCRHOADDR1EGLN1 | |
| SCHEMBL28050273 | 0.80 | RXRA (0.43) | TACR1DDR1RXRARXRBRXRG | |
| SCHEMBL13753113 | 0.80 | ALDH1A1 (0.65) | TACR1RHOCRHOADDR1MLYCD | |
| SCHEMBL28115901 | 0.80 | RHOC (0.48) | TACR1RHOCRHOADDR1VNN1 | |
| SCHEMBL25421238 | 0.79 | TACR1 (0.48) | TACR1RHOCRHOADDR1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419419-B1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-03 | — | — | EP | disclosed |
| US-8513229-B2 | 4-Azetidinyl-1-phenyl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-20 | — | — | US | disclosed |
| US-8450304-B2 | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| CN-102459227-A | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 | JANSSEN PHARMACEUTICA NV | 2012-05-16 | — | — | CN | disclosed |
| EP-2419419-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2012-02-22 | — | — | EP | disclosed |
| US-20120040960-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-16 | — | — | US | disclosed |
| CN-102317278-A | The 4-azetidinyl of CCR2-1-heteroaryl-hexalin antagonist | JANSSEN PHARMACEUTICA NV | 2012-01-11 | — | — | CN | disclosed |
| WO-2010121046-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267689-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N. V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040960-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | TACR1 65/4885RHOC 3375/4885RHOA 3259/4885 |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCRL2 | TACR1 104/4885RHOC 3379/4885RHOA 3786/4885 |
| US-20100267689-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | TACR1 65/4885RHOC 3375/4885RHOA 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.